October 29, 2015
Sumitomo Dainippon President Masayo Tada Sumitomo Dainippon Pharma will make its third attempt for a PIII trial of its atypical antipsychotic lurasidone, sold as Latuda overseas, to obtain data to seek approval in Japan for the treatment of schizophrenia, President...read more